Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CMA1 | P23946 | 15/20 | 0.52 |
| ▸ | ELANE | P08246 | 5/20 | 0.49 |
| ▸ | CTSG | P08311 | 1/20 | 0.48 |
| ▸ | CTRC | Q99895 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6740047 | 0.87 | ELANE (0.46) | ELANECTSG | |
| SCHEMBL6745052 | 0.86 | CMA1 (0.53) | CMA1ELANE | |
| SCHEMBL6741140 | 0.81 | ELANE (0.61) | CMA1ELANECTSG | |
| SCHEMBL6743718 | 0.80 | ELANE (0.48) | CMA1ELANECTSG | |
| SCHEMBL13164551 | 0.76 | ELANE (0.52) | ELANE | |
| SCHEMBL24109060 | 0.75 | CMA1 (0.54) | CMA1CTRC | |
| SCHEMBL7337411 | 0.74 | ELANE (0.62) | CMA1ELANECTSG | |
| SCHEMBL30896685 | 0.74 | CAPN1 (0.53) | CMA1 | |
| SCHEMBL19899288 | 0.73 | HTRA1 (0.55) | — | |
| SCHEMBL19899291 | 0.73 | HTRA1 (0.55) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6693072-B2 | Elastase inhibitors | AVENTIS PHARMACEUTICALS INC. | 2004-02-17 | — | — | US | disclosed |
| EP-0804465-B1 | NOVEL ELASTASE INHIBITORS | AVENTIS PHARMA INC (US) | 2003-08-06 | — | — | EP | disclosed |
| US-20030096759-A1 | Novel elastase inhibitors | AVENTISUB II INC. | 2003-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030096759-A1 | Novel elastase inhibitors | ELANE, SERPINB1, MMP8 | CMA1 75/4885ELANE 1/4885CTSG 91/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.